CClinicalTrials.gg
CompletedNCT03292003Updated Mar 28, 2019

Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study

An observational study in Total Knee Arthroplasty, sponsored by Smith & Nephew, Inc.. Completed at 12 sites in 3 countries. Per ClinicalTrials.gov, last updated 2019-03-28.

Sponsored by Smith & Nephew, Inc. · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1,694
Sex
All
01

Study summary

The objective of this study is to estimate the safety and performance of Journey II BCS TKS.

Read the detailed description

The objective of this study is to estimate the safety and performance of Journey II BCS TKS. Specifically, the study will establish revision rate, treatment- and device-related complications, and clinical outcomes in a large sample of subjects who received the study device. Subjects are screened consecutively, beginning at the earliest date of implantation at each investigative site. Further, reasons for revision will be collected and analyzed. An analysis will be performed to identify characteristics (patient, surgeon and surgical) associated with an increased risk for revision. Finally, clinical, functional and quality of life outcomes will be analyzed to the extent data is available, given the retrospective study design.

02

Conditions studied

  • Total Knee Arthroplasty

Keywords

  • rheumatoid arthritis
  • post-traumatic arthritis
  • osteoarthritis
  • degenerative arthritis
  • failed osteotomy
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Sites will identify potential subjects by retrospectively reviewing their source documents in order to identify all patients who received TKA with the Journey II BCS TKS.

Inclusion criteria

  • Subject received primary uni- or bi-lateral total knee arthroplasty with the Journey II BCS Total Knee System for approved indication
  • The TKA occurred at least 12 weeks prior to enrollment
  • Subject records contain Patient Reported Outcome data obtained ≤3 months prior to as well as ≥6 months post-enrollment.

Exclusion criteria

Exclusion Criteria:

  • Subject received the JOURNEY II BCS Total Knee System on the affected knee as a revision for a previously failed total or unicondylar knee arthroplasty
04

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1,694 participants (actual)
Patient registry
No

Groups and cohorts

  • Journey II BCS Total Knee System

    Subjects having TKA with Journey II BCS Total Knee System

    Device: Journey II BCS Total Knee System

Interventions

  • DeviceJourney II BCS Total Knee System
05

What researchers measure

Primary outcomes

  1. Revision Rate of Total Knee System

    Number of revisions

    Time frame: implantation through study completion, approximately 3 years

Secondary outcomes

  1. Adverse Events

    Number of adverse events reported per ISO 14155 guidelines

    Time frame: implantation through study completion, approximately 3 years

  2. Health care utilization: Hospitalization

    Length of hospital stay for primary (index) surgery

    Time frame: implantation through study completion, approximately 3 years

  3. Health care utilization: Hospitalization

    Hospitalizations (admission for inpatient care) occurring after the hospitalization for the index surgery (number and length of stay)

    Time frame: implantation through study completion, approximately 3 years

  4. Health care utilization: Rehabilitation

    number of sessions and duration of rehabilitation in weeks

    Time frame: implantation through study completion, approximately 3 years

  5. Health care utilization: Outpatient visits

    Number and type of outpatient visits

    Time frame: implantation through study completion, approximately 3 years

  6. Health Care Utilization: Re-operations

    number of re-operations and revisions

    Time frame: implantation through study completion, approximately 3 years

  7. Patient reported outcomes

    EQ-5D-3L

    Time frame: implantation through study completion, approximately 3 years

  8. Clinical outcomes

    Knee Society Score

    Time frame: implantation through study completion, approximately 3 years

  9. Return to Work

    Changes in employment status will be recorded with the date on which the change occurred and the change status.

    Time frame: implantation through study completion, approximately 3 years

  10. Technical Difficulties Encountered During Device Implantation

    Number of technical difficulties encountered with the device

    Time frame: implantation through study completion, approximately 3 years

06

Study locations

12 sites
  • University of Colorado Orthopaedics
    Aurora, Colorado 80045, United States
  • Andrews Research and Education Foundation
    Gulf Breeze, Florida 32571, United States
  • Methodist Sports Medicine
    Indianapolis, Indiana 46280, United States
  • Hospital for Special Surgery
    New York, New York, United States
  • University Orthopaedics Center
    State College, Pennsylvania 16602, United States
  • TN Orthopaedic Foundation for Education and Research
    Knoxville, Tennessee 37923, United States
  • San Antonio Orthopaedic Specialists
    San Antonio, Texas 78258, United States
  • Providence Regional Medical Center
    Everett, Washington 98021, United States
  • Marra Knee and Shoulder Center
    Wheeling, West Virginia 26003, United States
  • Jesse Ziekenhuis
    Hasselt, Belgium
  • UZ Leuven Campus
    Pellenberg, Belgium
  • Christen Ortho AG
    Bern, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03292003
Lead sponsor
Smith & Nephew, Inc.
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Dec 30, 2016
Primary completion
Jan 30, 2018
Completion
Sep 24, 2018
Last update
Mar 28, 2019

Study contacts

Beate Hanson, MD, PhD
study chair · Vice President, Global Clinical Strategy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion